Core Insights - QuidelOrtho Corporation has launched the QUICKVUE Influenza + SARS Test, a rapid immunoassay designed for professional use in various healthcare settings [1][2][3] - The test allows for rapid detection of influenza A, influenza B, and SARS-CoV-2 from a single sample, providing results within 10 minutes, which aids in differentiating between COVID-19 and seasonal flu [3][7] - The launch is expected to significantly enhance QuidelOrtho's Molecular Diagnostics and Point of Care business units, strengthening its market position [2][4] Company Developments - The QUICKVUE Influenza + SARS Test expands QuidelOrtho's respiratory solutions portfolio and is currently available in the U.S. through existing distribution channels [2][7] - In August, QuidelOrtho reported strong growth in Molecular Diagnostics revenues for Q2 2025, indicating robust performance in this segment [5][8] Industry Prospects - The global point-of-care diagnostics market is projected to grow from $47.8 billion in 2024 to $68.5 billion by 2030, at a CAGR of 5.8%, driven by the demand for immediate results and technological advancements [4] - The recent product launch is anticipated to provide a significant boost to QuidelOrtho's business, capitalizing on the growing market potential [4] Peer Comparison - Qiagen N.V. received CE-IVDR certification for its QIAstat-Dx testing systems, enhancing its diagnostic capabilities [6] - Hologic, Inc. reported strong growth in Diagnostics revenues, driven by increased sales of its assays [7][8] - Thermo Fisher Scientific Inc. also reported robust Specialty Diagnostics revenues and launched new solutions to support clinical laboratories [9]